Research programme: protease enzyme inhibitors - Paradigm Therapeutics

Drug Profile

Research programme: protease enzyme inhibitors - Paradigm Therapeutics

Latest Information Update: 13 Feb 2008

Price : $50

At a glance

  • Originator Paradigm Therapeutics
  • Developer Takeda Cambridge
  • Class Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Cancer; Viral infections

Most Recent Events

  • 27 Apr 2007 No development reported - Preclinical for Viral infections in United Kingdom (unspecified route)
  • 27 Apr 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
  • 27 Apr 2007 No development reported - Preclinical for Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top